The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
What are regulatory T cells (Treg) regulating in cancer and why?
Open accessAbstract
The role regulatory T cells (Treg) play in cancer development and progression is not clear. Earlier evidence suggested that CD4+FOXP3+CD25high Treg accumulate in tumors and the peripheral blood of patients with cancer and through suppression of anti-tumor immune responses promote tumor growth. However, more recent data indicate that in certain cancers, such as colorectal carcinoma (CRC), Treg suppress bacteria-driven inflammation which promotes carcinogenesis and thus benefit the host. Treg appear to play a dual role in cancer. This might explain why the frequency and functions of Treg are associated with a poor prognosis in some cancers but with favorable outcome in others. The clinical and prognostic significance of Treg in cancer depends on environmental factors, including infectious agents, tumor-derived products and locally-produced cytokines, which shape the nature of immune responses, including Treg generation, recruitment and survival. Adaptive or inducible (i) Treg or Tr1 are the major subset(s) of Treg present in cancer. These iTreg are a distinct subset of regulatory cells that phenotypically and functionally differ from FOXP3+ natural (n) Treg responsible for peripheral tolerance. They mediate powerful suppression of effector T cells via diverse mechanisms, produce immunosuppressive cytokines, notably TGF-β as well as prostaglandin E2 and adenosine, and are resistant to apoptosis or oncological therapies. Strategies for silencing of Tr1 in patients with cancer will require novel approaches that can selectively deplete these cells or block molecular pathways they utilize.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Self-citationSato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940 · cited 1×
“Many human tumors are preceded by or associated with inflammation [80].”
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Wang, D., & DuBois, R. N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2809 · Cited by 1,793
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Shevach, E. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.010 · Cited by 1,754
CD4+CD25+ Immunoregulatory T Cells
McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286
Jonuleit, H., Schmitt, E., Stassen, M., Tuettenberg, A., Knop, J., & Enk, A. H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1285 · Cited by 1,255
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans
Grazia Roncarolo, M., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., & Levings, M. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00420.x · Cited by 1,173
Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,054
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
Transient expression of FOXP3 in human activated nonregulatory CD4 + T cells
Wang, J., Ioan‐Facsinay, A., van der Voort, E. I. H., Huizinga, T. W. J., & Toes, R. E. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636435 · Cited by 1,011
Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., & Iacopetta, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7229 · Cited by 991
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 911
Roncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S., & Levings, M. K. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820105.x · Cited by 814
Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208249 · Cited by 813
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells
Haxhinasto, S., Mathis, D., & Benoist, C. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071477 · Cited by 737
Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers
Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N. E. H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1886 · Cited by 598
Inflammation and Cancer: IL-6 and STAT3 Complete the Link
Bromberg, J., & Wang, T. C. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.009 · Cited by 542
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492
Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J. T., & Whiteside, T. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0472 · Cited by 453
Self-citationTumor-Driven Evolution of Immunosuppressive Networks during Malignant Progression
Kim, R., Emi, M., Tanabe, K., & Arihiro, K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4128 · Cited by 445
(1997) · PubMed · Cited by 433
Petersen, R. P., Campa, M. J., Sperlazza, J., Conlon, D., Joshi, M., Harpole, D. H., & Patz, E. F. (2006) · Cancer · doi:10.1002/cncr.22282 · Cited by 433
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
Campoli, M., & Ferrone, S. (2008) · Oncogene · doi:10.1038/onc.2008.273 · Cited by 404
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
Ercolini, A. M., Ladle, B. H., Manning, E. A., Pfannenstiel, L. W., Armstrong, T. D., Machiels, J.-P. H., Bieler, J. G., Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042167 · Cited by 399
Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target
Sojka, D. K., Huang, Y., & Fowell, D. J. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02813.x · Cited by 393 · cited 1×
“It is necessary to remember that several different molecular pathways responsible for Treg-mediated suppression exist [35-37, 74] and may or may not be utilized by FOXP3+CD25high Treg.”
Mandapathil, M., Hilldorfer, B., Szczepanski, M. J., Czystowska, M., Szajnik, M., Ren, J., Lang, S., Jackson, E. K., Gorelik, E., & Whiteside, T. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.047423 · Cited by 390
Self-citation(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07003-x · Cited by 386
Induction, function and regulation of IL‐17‐producing T cells
Mills, K. H. G. (2008) · European Journal of Immunology · doi:10.1002/eji.200838535 · Cited by 385
Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates
Fridman, W. H., Galon, J., Pagès, F., Tartour, E., Sautès-Fridman, C., & Kroemer, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1316 · Cited by 380
Frey, D. M., Droeser, R. A., Viehl, C. T., Zlobec, I., Lugli, A., Zingg, U., Oertli, D., Kettelhack, C., Terracciano, L., & Tornillo, L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24989 · Cited by 333
Ladoire, S., Martin, F., & Ghiringhelli, F. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1046-y · Cited by 331
Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma
Doubrovina, E. S., Doubrovin, M. M., Vider, E., Sisson, R. B., O’Reilly, R. J., Dupont, B., & Vyas, Y. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6891 · Cited by 324
Franceschini, D., Paroli, M., Francavilla, V., Videtta, M., Morrone, S., Labbadia, G., Cerino, A., Mondelli, M. U., & Barnaba, V. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36604 · Cited by 318
Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Mueller-Berghaus, J., Kirkwood, J. M., Kwok, W. W., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012142 · Cited by 314
CCR6 expression defines regulatory effector/memory-like cells within the CD25+CD4+ T-cell subset
Kleinewietfeld, M., Puentes, F., Borsellino, G., Battistini, L., Rötzschke, O., & Falk, K. (2005) · Blood · doi:10.1182/blood-2004-07-2505 · Cited by 312
Foxp3: a critical regulator of the development and function of regulatory T cells
Hori, S., & Sakaguchi, S. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.02.020 · Cited by 291
Rech, A. J., & Vonderheide, R. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04939.x · Cited by 289
CD39 and control of cellular immune responses
Dwyer, K. M., Deaglio, S., Gao, W., Friedman, D., Strom, T. B., & Robson, S. C. (2007) · Purinergic Signalling · doi:10.1007/s11302-006-9050-y · Cited by 289
Schenk, U., Frascoli, M., Proietti, M., Geffers, R., Traggiai, E., Buer, J., Ricordi, C., Westendorf, A. M., & Grassi, F. (2011) · Science Signaling · doi:10.1126/scisignal.2001270 · Cited by 286
Strauss, L., Bergmann, C., Gooding, W., Johnson, J. T., & Whiteside, T. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1403 · Cited by 281
Self-citationSitkovsky, M. V., Kjaergaard, J., Lukashev, D., & Ohta, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0229 · Cited by 253
Lymphocytes in cancer development: Polarization towards pro-tumor immunity
Ruffell, B., DeNardo, D. G., Affara, N. I., & Coussens, L. M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.002 · Cited by 253
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Jacobs, J. F., Nierkens, S., Figdor, C. G., de Vries, I. J. M., & Adema, G. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70155-3 · Cited by 245
Hoskin, D., Mader, J., Furlong, S., Conrad, D., & Blay, J. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.3.527 · Cited by 242
Expression of CD39 by Human Peripheral Blood CD4+CD25+ T Cells Denotes a Regulatory Memory Phenotype
Dwyer, K. M., Hanidziar, D., Putheti, P., Hill, P. A., Pommey, S., McRae, J. L., Winterhalter, A., Doherty, G., Deaglio, S., Koulmanda, M., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03291.x · Cited by 216
Foxp3 expression in human cancer cells
Karanikas, V., Speletas, M., Zamanakou, M., Kalala, F., Loules, G., Kerenidi, T., Barda, A. K., Gourgoulianis, K. I., & Germenis, A. E. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-19 · Cited by 216
Strauss, L., Bergmann, C., & Whiteside, T. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1469 · Cited by 214
Self-citationReichert, T. E., Strauss, L., Wagner, E. M., Gooding, W. E., & Whiteside, T. L. (2002) · PubMed · Cited by 211
Self-citationCorreale, P., Rotundo, M. S., Del Vecchio, M. T., Remondo, C., Migali, C., Ginanneschi, C., Tsang, K. Y., Licchetta, A., Mannucci, S., Loiacono, L., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32f01 · Cited by 210
Perrone, G., Ruffini, P. A., Catalano, V., Spino, C., Santini, D., Muretto, P., Spoto, C., Zingaretti, C., Sisti, V., Alessandroni, P., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.017 · Cited by 210
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
Oble, D. A., Loewe, R. P., Yu, P., & Mihm, M. C. (2009) · PubMed · Cited by 207
Immune responses to malignancies
Whiteside, T. L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.045 · Cited by 204
Self-citationExploring the link between microorganisms and oral cancer: A systematic review of the literature
Hooper, S. J., Wilson, M. J., & Crean, S. J. (2009) · Head & Neck · doi:10.1002/hed.21140 · Cited by 202
Chemotherapy and radiotherapy: Cryptic anticancer vaccines
Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., Tesniere, A., Martins, I., Ly, A., Haynes, N. M., et al. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.001 · Cited by 193
Mandapathil, M., Szczepanski, M. J., Szajnik, M., Ren, J., Lenzner, D. E., Jackson, E. K., Gorelik, E., Lang, S., Johnson, J. T., & Whiteside, T. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1143 · Cited by 182
Self-citationAn evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0987-8 · Cited by 180
FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease
Kryczek, I., Liu, R., Wang, G., Wu, K., Shu, X., Szeliga, W., Vatan, L., Finlayson, E., Huang, E., Simeone, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3804 · Cited by 179
Is FOXP3 a bona fide marker for human regulatory T cells?
Roncarolo, M., & Gregori, S. (2008) · European Journal of Immunology · doi:10.1002/eji.200838168 · Cited by 174
Schulze zur Wiesch, J., Thomssen, A., Hartjen, P., Tóth, I., Lehmann, C., Meyer-Olson, D., Colberg, K., Frerk, S., Babikir, D., Schmiedel, S., et al. (2011) · Journal of Virology · doi:10.1128/jvi.01758-10 · Cited by 173
Camouflage and sabotage: tumor escape from the immune system
Poschke, I., Mougiakakos, D., & Kiessling, R. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1012-8 · Cited by 169
Strauss, L., Bergmann, C., Szczepanski, M. J., Lang, S., Kirkwood, J. M., & Whiteside, T. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.2967 · Cited by 165
Self-citationMandapathil, M., Lang, S., Gorelik, E., & Whiteside, T. L. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.05.004 · Cited by 163
Self-citationMandapathil, M., Szczepanski, M. J., Szajnik, M., Ren, J., Jackson, E. K., Johnson, J. T., Gorelik, E., Lang, S., & Whiteside, T. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127100 · Cited by 162
Self-citationProstaglandin E2 promotes intestinal tumor growth via DNA methylation
Xia, D., Wang, D., Kim, S.-H., Katoh, H., & DuBois, R. N. (2012) · Nature Medicine · doi:10.1038/nm.2608 · Cited by 161
Immunobiology of head and neck cancer
Whiteside, T. L. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-5050-6 · Cited by 161
Self-citationMenning, A., Höpken, U. E., Siegmund, K., Lipp, M., Hamann, A., & Huehn, J. (2007) · European Journal of Immunology · doi:10.1002/eji.200737201 · Cited by 160
Lan, Q., Fan, H., Quesniaux, V., Ryffel, B., Liu, Z., & Guo Zheng, S. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjr039 · Cited by 160
Bergmann, C., Strauss, L., Wang, Y., Szczepański, M. J., Lang, S., Johnson, J. T., & Whiteside, T. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5126 · Cited by 159
Self-citationTGF- and 'Adaptive' Foxp3+ Regulatory T cells
Chen, W., & Konkel, J. E. (2009) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjp004 · Cited by 156
Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways
Zhang, Y.-L., Li, J., Mo, H., Qiu, F., Zheng, L., Qian, C.-N., & Zeng, Y.-X. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-4 · Cited by 155
Bergmann, C., Strauss, L., Zeidler, R., Lang, S., & Whiteside, T. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0767 · Cited by 153
Self-citationCD49d provides access to “untouched” human Foxp3+ Treg free of contaminating effector cells
Kleinewietfeld, M., Starke, M., Mitri, D. D., Borsellino, G., Battistini, L., Rötzschke, O., & Falk, K. (2008) · Blood · doi:10.1182/blood-2008-04-150524 · Cited by 145
Moncrieffe, H., Nistala, K., Kamhieh, Y., Evans, J., Eddaoudi, A., Eaton, S. D., & Wedderburn, L. R. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0803474 · Cited by 142
Bohling, S. D., & Allison, K. H. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.160 · Cited by 139
Peters, J. H., Preijers, F. W. M. B., Woestenenk, R., Hilbrands, L. B., Koenen, H. J. P. M., & Joosten, I. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003161 · Cited by 132
Zhang, Y., Liu, Q., Zhang, M., Yu, Y., Liu, X., & Cao, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801548 · Cited by 124
Audia, S., Nicolas, A., Cathelin, D., Larmonier, N., Ferrand, C., Foucher, P., Fanton, A., Bergoin, E., Maynadié, M., Arnould, L., et al. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03521.x · Cited by 123
The Role of Immune Cells in the Tumor Microenvironment
Whiteside, T. L. (2006) · Cancer treatment and research · doi:10.1007/0-387-26283-0_5 · Cited by 119
Self-citationThe prognostic impact of anti-cancer immune response: a novel classification of cancer patients
Bindea, G., Mlecnik, B., Fridman, W. H., & Galon, J. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0264-x · Cited by 113
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers.
Uppaluri, R., Dunn, G. P., & Lewis, J. S. (2008) · PubMed · Cited by 112
Perez, S. A., Karamouzis, M. V., Skarlos, D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2347 · Cited by 111
Tumor Microenvironment and Immune Escape
Ferrone, S., & Whiteside, T. L. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.08.004 · Cited by 99
Self-citationKesselring, R., Thiel, A., Pries, R., Trenkle, T., & Wollenberg, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605891 · Cited by 98
Signaling defects in anti‐tumor T cells
Frey, A. B., & Monu, N. R. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00606.x · Cited by 91
Cancer inflammation and regulatory T cells
Erdman, S. E., & Poutahidis, T. (2010) · International Journal of Cancer · doi:10.1002/ijc.25430 · Cited by 83
Schuler, P. J., Harasymczuk, M., Schilling, B., Lang, S., & Whiteside, T. L. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.04.004 · Cited by 82
Self-citationWhiteside, T. L., Mandapathil, M., & Schuler, P. J. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711798184334 · Cited by 79
Self-citationde Vries, I. J. M., Castelli, C., Huygens, C., Jacobs, J. F. M., Stockis, J., Schuler‐Thurner, B., Adema, G. J., Punt, C. J. A., Rivoltini, L., Schuler, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2227 · Cited by 78
Naturally Occurring Regulatory T Cells: Recent Insights in Health and Disease
Raimondi, G., Turner, M. S., Thomson, A. W., & Morel, P. A. (2007) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v27.i1.50 · Cited by 72
Schmidt, A., Oberle, N., Weiss, E., Vobis, D., Frischbutter, S., Baumgrass, R., Falk, C. S., Haag, M., Brügger, B., Lin, H., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2002179 · Cited by 65
Strauss, L., Bergmann, C., & Whiteside, T. L. (2007) · International Journal of Cancer · doi:10.1002/ijc.23001 · Cited by 63
Self-citationSa, G., Das, T., Moon, C., Hilston, C. M., Rayman, P. A., Rini, B. I., Tannenbaum, C. S., & Finke, J. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3776 · Cited by 61
Imai, N., Ikeda, H., Tawara, I., & Shiku, H. (2008) · European Journal of Immunology · doi:10.1002/eji.200838824 · Cited by 52
Elkord, E., Sharma, S., Burt, D. J., & Hawkins, R. E. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.04.014 · Cited by 51
Disarming suppressor cells to improve immunotherapy
Whiteside, T. L. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1171-7 · Cited by 47
Self-citationCzystowska, M., Strauss, L., Bergmann, C., Szajnik, M. E., Rabinowich, H., & Whiteside, T. L. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0602-9 · Cited by 45
Self-citationRech, A. J., Mick, R., Kaplan, D. E., Chang, K., Domchek, S. M., & Vonderheide, R. H. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0780-x · Cited by 38
To Be or Not to Be a T reg Cell: Lineage Decisions Controlled by Epigenetic Mechanisms
Toker, A., & Huehn, J. (2011) · Science Signaling · doi:10.1126/scisignal.2001783 · Cited by 37
Costimulatory signals controlling regulatory T cells
Ermann, J., & Fathman, C. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307001100 · Cited by 34
Eggermont, A. M. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2377 · Cited by 29
Zarek, P. E., & Powell, J. D. (2007) · Autoimmunity · doi:10.1080/08916930701464939 · Cited by 27
Alpizar, Y. A., Chain, B., Collins, M. K., Greenwood, J., Katz, D. R., Stauss, H. J., & Mitchison, N. A. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0985-7 · Cited by 25
Depletion of Human Regulatory T Cells
Hobeika, A. C., Morse, M. A., Osada, T., Peplinski, S., Lyerly, H. K., & Clay, T. M. (2011) · Methods in molecular biology · doi:10.1007/978-1-61737-979-6_14 · Cited by 19
Cited by
Forkhead box proteins: tuning forks for transcriptional harmony.
Lam, E. W.-F., Brosens, J. J., Gomes, A. R., & Koo, C.-Y. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3539 · Cited by 684
Madrigal, M., Rao, K. S., & Riordan, N. H. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0260-8 · Cited by 615
Chaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Immune system: a double-edged sword in cancer
Lakshmi Narendra, B., Eshvendar Reddy, K., Shantikumar, S., & Ramakrishna, S. (2013) · Inflammation Research · doi:10.1007/s00011-013-0645-9 · Cited by 206
The tumour microenvironment and immune milieu of cholangiocarcinoma
Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., Solinas, A., Sänger, H., Lukacs‐Kornek, V., Moncsek, A., et al. (2019) · Liver International · doi:10.1111/liv.14098 · Cited by 187
Metadata
- Authors
- Whiteside, T. L.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 22
- Issue
- 4
- Pages
- 327-334
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2052071472
- Cited by
- 291
- References
- 118
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.